Delving into the Latest Updates on Shanghai Kaiyi Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Taste 2 receptors	1

Primary objective: To evaluate the efficacy of kubutan saponin A inhalation solution in patients with moderate chronic obstructive pulmonary disease (COPD) for 29 consecutive days. Secondary objective: To evaluate the safety of kubutan saponin A inhalation solution in patients with moderate chronic obstructive pulmonary disease (COPD) for 29 consecutive days.

Start Date16 Apr 2024

Sponsor / Collaborator

Shanghai Kaiyi Pharmaceutical Technology Co., Ltd.

CTR20223064 / CompletedPhase 1

吸入用苦丁皂苷A溶液（KA溶液）单/多次给药在中重度慢性阻塞性肺疾病患者中的开放、安全性和药效学研究

[Translation] An open-label, safety and pharmacodynamic study of single/multiple administrations of inhaled kubutan saponin A solution (KA solution) in patients with moderate to severe chronic obstructive pulmonary disease

主要目的：评价中重度慢性阻塞性肺疾病（COPD）患者单/多次给予吸入用苦丁皂苷A溶液的安全性。次要目的：评价单/多次给予吸入用苦丁皂苷A溶液在中重度COPD患者中的药效学（PD）指标。

[Translation]

Primary objective: To evaluate the safety of single/multiple administrations of inhaled kudingsaponin A solution in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Secondary objective: To evaluate the pharmacodynamic (PD) indexes of single/multiple administrations of inhaled kudingsaponin A solution in patients with moderate to severe COPD.

Start Date14 Dec 2022

Sponsor / Collaborator

Shanghai Kaiyi Pharmaceutical Technology Co., Ltd.

CTR20221380 / CompletedPhase 1

吸入用苦丁皂苷A溶液多次给药在健康志愿者中的随机、双盲、剂量递增、安慰剂平行对照的安全性、耐受性、药代动力学研究

[Translation] A randomized, double-blind, dose-escalation, placebo-controlled safety, tolerability, and pharmacokinetics study of multiple doses of inhaled kudingsaponin A solution in healthy volunteers

主要目的：观察在健康志愿者中多次给予不同剂量吸入用苦丁皂苷A溶液的安全性和耐受性。次要目的：考察多次给予不同剂量吸入用苦丁皂苷A溶液在健康志愿者中的药代动力学特征。

[Translation]

Primary objective: To observe the safety and tolerability of multiple administrations of different doses of inhaled kudingsaponin A solution in healthy volunteers. Secondary objective: To investigate the pharmacokinetic characteristics of multiple administrations of different doses of inhaled kudingsaponin A solution in healthy volunteers.

Start Date23 Jun 2022

Sponsor / Collaborator

Shanghai Kaiyi Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Shanghai Kaiyi Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Kaiyi Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Kaiyi Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Kaiyi Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data